Butyrate is the most interesting molecule in your gut that you do not eat. It is made in the colon when bacteria ferment fibre, it is the preferred fuel of the cells lining the colon, and low levels of it track with almost every bad gut outcome anyone has looked at.[3][4] So the supplement pitch writes itself: if butyrate is that important, take butyrate. The problem is the one step the label never mentions. Short-chain fatty acids are absorbed very quickly in the upper gut, which means an ordinary butyrate capsule is largely gone into your bloodstream before it reaches the organ it is supposed to feed. Everything that matters about this category — enteric coatings, tributyrin, microencapsulation, and the honest case for just eating more fibre — falls out of that single fact.
What butyrate is, and why the colon is the whole story
Butyrate is a four-carbon short-chain fatty acid (SCFA) produced when colonic bacteria ferment fermentable fibre and resistant starch. It is not really a nutrient in the ordinary sense — it is a metabolite manufactured on site, in the organ that consumes it. Butyrate is the preferred substrate of colonocytes and appears to hold those cells in a normal phenotype; it also inhibits histone deacetylases and signals through three G-protein-coupled receptors, which is where the anti-inflammatory and barrier claims come from.[3][4]
The geography matters more than the biochemistry, and one 1987 study drew the map. Measuring SCFAs directly in the gut contents and blood of sudden-death victims, Cummings and colleagues found total SCFA concentrations of 13 mmol/kg in the terminal ileum against 131 mmol/kg in the caecum — a tenfold step up the moment the contents cross into the colon. In blood, total SCFA ran 375 µmol/L in the portal vein, 148 in the hepatic vein and 79 in peripheral blood, and the shifting molar ratios showed butyrate being preferentially extracted by the colonic epithelium itself.[1] Butyrate is made in the colon, eaten by the colon, and what escapes is largely cleared by the liver. Very little of it was ever meant to circulate.
That is also why fermentation is metabolically non-trivial: colonic SCFA production is estimated to supply somewhere around 5–10% of human energy requirements.[2] Hold on to that number. It is the reason the dose arithmetic below goes the way it does.
The delivery problem, stated plainly
Swallow sodium butyrate in a plain capsule and it dissolves in the stomach, and the free acid is absorbed rapidly across the proximal gut. The cleanest demonstration is a 2024 controlled study that gave healthy volunteers oral SCFA supplements and tracked serum concentrations by GC-MS. Uncoated capsules produced earlier and more intense peak serum concentrations; an acid-resistant coated capsule produced a delayed and blunted blood response. All the SCFAs peaked within 60 minutes and were back to baseline by 120 minutes. And a one-week, twice-daily regimen produced no change in basal serum SCFA concentrations.[5]
Read that the right way round. The blunted, delayed curve is the good outcome: the coating working means less of the dose entering blood early, because you wanted the butyrate further down. A spike in serum butyrate an hour after swallowing an uncoated capsule is not evidence of a delivered dose. It is evidence of a missed target.
Two much-cited supplementation trials from the same Amsterdam group make the same point from the other side, and they disagree with each other in a way worth knowing about. Four grams a day of oral sodium butyrate for four weeks in lean and metabolic-syndrome men produced no effect on plasma or faecal butyrate at all, though other SCFAs shifted.[25] The same 4 g/day dose for a month in people with long-standing type 1 diabetes did significantly change faecal butyrate and propionate — but changed nothing else, in any immune or metabolic outcome measured.[26] Even at a research dose several times what a commercial product delivers, whether the butyrate you swallow ever registers where it is supposed to is genuinely unsettled.
The dose-scale reality check
This is the single most useful thing to know before buying anything in this category, and it is arithmetic rather than opinion.
A 2025 randomised trial measured intestinal butyrate production directly, using an intravenous 13C-labelled SCFA tracer with compartmental modelling in 21 young and 40 older adults. Baseline butyrate production in the pool the authors interpret as intestinal ran 14 µmol/min in older adults and 28 µmol/min in young adults. Seven days of 30 g/day inulin raised it by 44% — to 20 and 44 µmol/min respectively — alongside a 50–60% rise in faecal SCFAs and a 34% rise in plasma butyrate in the older group.[10]
Convert those rates to a day. 14–44 µmol/min is roughly 20–63 mmol of butyrate per day, or about 1.8–5.6 grams. Now price a capsule: sodium butyrate has a molar mass of about 110 g/mol, so a 300 mg capsule contains roughly 2.7 mmol of butyrate, and a 600 mg capsule about 5.4 mmol. Even the 4 g/day research dose used in the Amsterdam trials is about 36 mmol — finally on the same scale as fermentation, and still delivered into the wrong end of the gut.[25][26]
A second angle from a different direction gives the same answer. In 46 healthy adults, faecal butyrate excretion at entry ranged from 0.3 to 18.2 mmol per 48 hours — and that is only the leftovers, what the colon failed to absorb.[11] At the top of that range, the butyrate a person is throwing away each day exceeds what three capsules contain. The same study is a caution against over-reading any of this: baseline butyrate varied roughly tenfold between individuals, and while a high-resistant-starch diet raised it in most people, it often fell in those who started high.[11]
The formulations built to solve it — and what each has actually shown
Four engineering answers exist. Each has some evidence. Be precise about what kind.
pH-dependent and shellac coatings
The most direct human test coated 1 g sodium butyrate tablets with hydroxypropyl methylcellulose and shellac, labelled the butyrate with 13C, and gave them to 12 healthy subjects and 12 Crohn’s patients, using a 13CO2 breath test alongside a transit-time marker to locate where release actually happened. The coating delayed release by 2–3 hoursrelative to uncoated tablets and delivered butyrate to the ileocaecal region and colon in all subjects, including Crohn’s patients with faster transit.[6] That is a genuine, well-designed demonstration — of delivery. The study measured no clinical endpoint at all.
Tributyrin, the triglyceride pro-drug
Tributyrin is glycerol esterified with three butyrate molecules — a neutral fat that occurs naturally in butter, survives the stomach, and releases butyrate on lipase digestion. Rodent pharmacokinetics established that oral tributyrin produces real plasma butyrate, with peaks 15–60 minutes after dosing and markedly non-linear clearance.[8] In humans, a phase I oncology study escalated tributyrin from 50 to 400 mg/kg/day in 13 patients: peak plasma butyrate reached 0 to 0.45 mM, approaching the 0.5–1 mM range active in cell culture — but butyrate had disappeared from plasma by 5 hours, which is why the authors moved to three-times-daily dosing.[7] Note the doses. For a 70 kg adult, 50–400 mg/kg/day is 3.5–28 grams a day. A tributyrin supplement typically supplies 500–1,500 mg. The human PK data does not transfer.
The most recent tributyrin work is a 2026 open-label study in 14 people with Parkinson’s disease and 3 controls, 500 mg three times daily for 30 days, with 11C-butyrate PET imaging before and after. It confirmed target engagement — organ-specific changes in butyrate availability — and reported good tolerability.[9] It was open-label with no placebo arm, so its cognitive and motor findings are hypothesis-generating and nothing more. Note also that tributyrin is solving a different problem than a colonic coating: it aims at systemic butyrate exposure, which colonocyte uptake and hepatic first-pass otherwise strip out.[1][9] The two formats are not interchangeable, and a product should tell you which target it is chasing.
Microencapsulation in a lipid or triglyceride matrix
This is the format used in most European clinical work and in most of the IBS and IBD trials below. It is also the format with the least published delivery data: the trials report symptoms and microbiota, not where the butyrate landed. The strongest indirect evidence is that microencapsulated sodium butyrate reproducibly shifts colonic bacterial populations — increasing SCFA-producing Lachnospiraceae in ulcerative colitis and Butyricicoccus in Crohn’s — which is hard to explain if none of it reached the colon.[23] Suggestive, not the same as a breath-test map.
Butyrate bound to fibre (butyrylated starch)
The most elegant solution barely gets sold as a supplement: esterify butyrate onto high-amylose maize starch so it travels bound to an indigestible carrier and is released by bacteria in the colon. In 41 healthy active adults, 20 g of butyrylated high-amylose maize starch twice daily for 28 days raised total faecal butyrate by 260% and bound butyrate by 950% versus a control starch.[13] Colonic delivery: unambiguous. The outcome half is more sober — plasma IL-10 and TNF-α shifted, but no other index of immunity changed.[13] The same material moved a surrogate cancer-risk marker in a crossover trial: 40 g/day of butyrylated starch restored the oncogenic miR17-92 cluster in rectal mucosa to baseline after a high-red-meat diet had raised it.[14] A microRNA in a biopsy is not a tumour, and the authors framed the result as support for eating more resistant starch — not for buying butyrate.
| Delivery route | What has actually been demonstrated |
|---|---|
| Fermentable fibre (inulin, resistant starch) | Production and delivery: 30 g/day inulin raised measured butyrate production 44%; resistant starch raises faecal butyrate in most people. Cheapest route, largest effect on colonic butyrate. |
| Plain uncoated capsule | Delivery failure: uncoated oral SCFA gives early, intense serum peaks gone by 2 hours. No trial shows an uncoated capsule reaching the colon. |
| Enteric / shellac-coated tablet | Delivery confirmed by 13C breath test to the ileocaecal region and colon in healthy and Crohn's subjects — no clinical endpoint measured in that study. |
| Microencapsulated (lipid matrix) | Most of the IBS and IBD trial evidence uses this format; delivery itself is inferred from microbiota shifts rather than directly mapped. |
| Tributyrin (triglyceride pro-drug) | Systemic exposure confirmed: measurable plasma butyrate in a phase I study at 3.5–28 g/day, cleared by 5 hours; PET target engagement in a 17-person open-label study. Aims at blood, not colon. |
| Butyrylated resistant starch | Colonic delivery confirmed: +260% total faecal butyrate. Immune outcomes largely unchanged; one surrogate cancer-risk marker moved. |
| Rectal enema (100 mmol/L) | The only route that puts butyrate straight on distal colonic mucosa. Positive in a 10-patient crossover, negative in the larger controlled trial, minor effects in remission. |
Evidence by indication
Irritable bowel syndrome — the best case, and it is small
IBS is where oral butyrate has its most consistent placebo-controlled support. The original trial randomised 66 IBS patients already on standard therapy to add microencapsulated sodium butyrate or placebo. At four weeks, pain during defaecation fell significantly; at twelve weeks, urgency and bowel habit improved. But the honest reading is in the abstract’s own qualifier: reductions in abdominal pain, flatulence and disordered defaecation were not statistically significant, and the drug reduced the frequency of selected symptoms without significantly reducing their severity.[15]
The strongest single result is a 2025 paediatric trial: 51 children with Rome IV IBS given 500 mg/day calcium butyrate or placebo for eight weeks, with treatment success (a 50% or greater drop on a visual analogue scale) in 73% versus 3.8%.[16] That is an enormous effect size, and the reason to be careful about it is the placebo arm. A 3.8% response rate in paediatric functional gut disease is far below the 30–50% placebo response these trials normally see; a result that large in 51 children needs replication in a bigger, independent cohort before it means what it appears to mean.
You will also see a “3,000-patient study” cited for butyrate in IBS. It is real, and it is an uncontrolled observational survey — 3,000 patients on 150 mg twice daily for 12 weeks with no placebo group, outcomes by questionnaire, partially funded by the manufacturer.[17] Large N does not substitute for a control arm in a condition with a placebo response that size. Treat it as a tolerability dataset, which is what it genuinely is.
Ulcerative colitis and IBD — where the rectal literature actually lives
Rectal butyrate is a different intervention, older and better characterised, and its results are instructive precisely because they are mixed. The landmark 1992 study treated 10 patients with treatment-refractory distal ulcerative colitis with 100 mmol/L sodium butyrate enemas in a single-blind crossover: stool frequency fell from 4.7 to 2.1 per day, bleeding stopped in 9 of 10 patients, and endoscopic and histological scores improved, with nothing changing on placebo.[19] Striking — and it is ten patients, single-blind.
The properly controlled follow-up did not replicate it. Thirty-eight patients with distal UC were randomised to nightly 60 mL 80 mmol/L butyrate enemas or saline: clinical improvement in 37% of the butyrate group versus 47% of placebo (p = 0.51), with identical 16% remission rates. The authors concluded butyrate enemas are not efficacious for distal UC.[20] A later trial in 35 patients in remission found rectal butyrate produced only minor effects on colonic inflammation and oxidative stress markers.[21]
Oral butyrate in IBD has generated more optimism than the trials support. A 30-patient pilot added colonic-targeted oral sodium butyrate 4 g/day to mesalazine in active UC: both arms improved significantly from baseline, and the difference between arms was not significant.[22] A 49-patient study of microencapsulated butyrate in IBD found microbiota shifts and improved quality of life in UC, with the authors stating outright that the clinical impact requires further investigation.[23] The largest is a 2026 randomised placebo-controlled trial in 140 IBD patients, which reported improved clinical disease activity (p = 0.013) and faecal calprotectin (p = 0.047) in Crohn’s, a marginal calprotectin reduction in UC (p = 0.09), and improved quality of life in both — with the effect concentrated in one microbiota enterotype.[24] That is the most substantial oral result in the field. It is also a subgroup-dependent finding with borderline p-values from a group with declared consultancy ties to the supplement’s maker, and it needs independent replication.
Gut barrier and inflammation
The barrier story has one clean human experiment, and it required a colonoscope. Seventeen IBS patients and 17 healthy volunteers had a defined colonic segment perfused with 100 mmol/L butyrate for 90 minutes in vivo; biopsies taken before and after were challenged in Ussing chambers. Deoxycholate-induced transcellular hyperpermeability was significantly reduced in post-exposure biopsies from IBS patients (p = 0.034).[18] That is direct, mechanistically satisfying evidence that butyrate protects the barrier — when you put butyrate on the barrier at 100 mmol/L through a scope. It says nothing about whether a capsule achieves anything comparable, and the authors do not claim it does.
For readers who arrived here from the leaky-gut literature, the same evidentiary gap shows up elsewhere in the category: see our monographs on larazotide, a tight-junction peptide with real mechanistic data and a failed Phase 3, and on KPV, where the anti-inflammatory biology is well described and the human trials are not there.
Metabolic claims — the most oversold section of the label
Two positive trials get quoted constantly. In 54 children with obesity, sodium butyrate at 20 mg/kg/day for six months on top of standard care produced BMI reduction of at least 0.25 SD scores in 96% versus 56% of controls, with improvements in waist circumference, insulin, HOMA-IR, ghrelin and IL-6.[29] It is a well-designed quadruple-blind trial; it is also 54 children at a single Italian centre, and the journal published a correction to its funding and support disclosure after publication.[30] Separately, a 2026 proof-of-concept trial gave 46 adults 1,875 mg/day sodium butyrate or placebo alongside an identical hypocaloric diet for 12 weeks: those without diabetes lost more weight (−7.0 vs −3.2 kg), while those with type 2 diabetes saw no weight difference but lower triglycerides and 9% more time in tight glycaemic range.[31] Promising — and with roughly a dozen people per cell, exactly the design that produces effects which shrink on replication.
Set against that, the null results are not obscure. Four grams a day for four weeks improved insulin sensitivity in lean men but not in metabolic syndrome, and the authors concluded their findings argue against oral butyrate as a treatment for glucose regulation in type 2 diabetes.[25] A month of 4 g/day in type 1 diabetes changed faecal SCFAs and nothing else — no innate immune, autoimmune, glucose, lipid or beta-cell effect.[26] And a 42-patient trial in type 2 diabetes found no significant between-group differences on any metabolic parameter, with within-group increases in total and LDL cholesterol on butyrate.[28] A separate trial did find butyrate downregulating inflammasome-pathway gene expression in type 2 diabetes, but the endpoints there are transcripts and microRNAs, not clinical outcomes.[27]
The fair summary of the metabolic literature: small trials, contradictory directions, endpoints that differ from study to study, and a review of the whole field concluding that clinical efforts to raise butyrate in humans have generated mixed results.[4] Nobody should be buying butyrate for weight loss on this evidence.
The fibre-first argument
Stated plainly: if your goal is more butyrate in your colon, fermentable fibre is the better-evidenced and cheaper intervention, and it is not close.
Fibre puts butyrate where butyrate belongs, because the butyrate is manufactured on site by the bacteria you are feeding. Thirty grams a day of inulin for one week raised measured butyrate production by 44% in both young and older adults, with faecal SCFAs up 50–60% — roughly 0.8–2 grams a day of additional butyrate, more than a typical capsule contains, delivered where it acts.[10] A meta-analysis of cereal-fibre trials found significant increases in butyrate (SMD 0.61) and total SCFAs across 14 intervention groups, though that pooled evidence base is itself only 205 participants.[12] Resistant starch raises faecal butyrate in most people.[11][3] Fibre also does several other things a butyrate capsule does not — stool bulk, transit, satiety, and every downstream benefit of the microbial community it feeds.
The honest caveats, because this is not a free lunch either. Response to fibre is highly individual: in the 46-adult resistant-starch study, baseline butyrate varied roughly tenfold and often decreased in people who started high.[11] Fermentable fibre also causes gas and bloating, and in IBS specifically it can make symptoms worse rather than better — which is the one clear situation where reaching for a delivered butyrate product instead of more fibre is a defensible choice.
And here is the negative claim, checked from the other side. No trial has randomised people to an oral butyrate supplement against a dose-matched fermentable fibre and compared outcomes. The nearest miss is a four-arm trial in 60 people with type 2 diabetes that ran 600 mg/day sodium butyrate, 10 g/day inulin, both together, and placebo for 45 days — but its endpoints were inflammasome gene expression, microRNAs and antioxidant markers, and it reported each arm against placebo rather than butyrate against inulin.[27] It is the only study design in the literature that could have answered the question people actually have, and it was not built to answer it.
Forms, doses, smell, tolerability and cost
Forms. Sodium butyrate is the most-studied and the cheapest. Calcium and magnesium butyrate are chemically equivalent as butyrate donors and mainly change the counter-ion — useful if you are watching sodium, but not a delivery upgrade in themselves; the 2025 paediatric IBS trial used calcium butyrate.[16] Tributyrin is a genuinely different molecule aimed at systemic exposure rather than colonic delivery.[7][9] The variable that actually matters on the label is whether the product does anything to survive the upper gut — enteric coating, shellac, a lipid or triglyceride matrix. A plain capsule of raw sodium butyrate is the one format with published evidence pointing the wrong way.[5]
Doses used in trials. The published range is wide and there is no established clinical dose. IBS work has used 150 mg twice daily and 500 mg/day;[17][16] metabolic trials have used 1,875 mg/day, 20 mg/kg/day and 4 g/day;[31][29][25] the UC add-on pilot used 4 g/day of a colonic-targeted tablet;[22] the Parkinson’s tributyrin study used 500 mg three times daily.[9] Commercial products typically sit at the low end of that, 300–600 mg/day. Nobody has established a dose-response curve, so nobody — including the label — knows what the right dose is.
The smell. This is not a minor practical detail. Butyric acid is the compound responsible for the smell of rancid butter and vomit, and it is detectable at very low concentrations. The lipid or triglyceride matrix in most commercial products exists partly to contain it. Capsules should be swallowed whole and never opened; a batch that smells strongly through the bottle is telling you something about the encapsulation. In the phase I tributyrin study, body odour was among the reported toxicities, alongside nausea, vomiting, diarrhoea, abdominal cramping and headache at oncology doses.[7]
Tolerability. At supplement doses the record is reassuring and unremarkable. The oral UC pilot reported no untoward side effects at 4 g/day for six weeks;[22] the paediatric obesity trial reported transient mild nausea and headache in 2 of 54 children over six months;[29] the type 1 diabetes crossover explicitly found butyrate treatment safe.[26] Sodium butyrate does contribute sodium, which is worth a thought at gram-level doses if you are managing blood pressure or fluid balance.
Cost. Butyrate salts are cheap commodity chemicals; what you pay for is the encapsulation, and that is the right thing to pay for. But run the comparison honestly: a month of a coated butyrate product generally costs meaningfully more than a month of psyllium, inulin or resistant starch that would raise colonic butyrate by more.[10] As with lactoferrin, the interesting question in this category is never the molecule — it is whether the delivery format has been shown to work.
The honest bottom line
Butyrate’s biology is not in doubt. It is the colonocyte’s preferred fuel, an HDAC inhibitor, a GPCR ligand, and a plausible lever on gut barrier and inflammation.[3][4] What is in doubt is whether swallowing a few hundred milligrams of it does anything useful, and the gap between those two statements is the entire product category.
Where the evidence lands: delivery has been demonstrated for coated tablets, butyrylated starch and tributyrin, each by a different measurement and none of them by the study that also measured a benefit. The best clinical case is IBS, on two small positive trials and one implausibly clean placebo arm.[15][16] IBD is genuinely interesting after a 140-patient trial, with borderline statistics, subgroup dependence and industry ties that make independent replication essential.[24] The rectal literature is older, better controlled, and its properly powered trial was negative.[20] The metabolic claims are the weakest part of the label and contradict themselves across trials.[25][28]
So: if you have IBS and fermentable fibre makes you worse, a coated or microencapsulated butyrate product is a reasonable, cheap, low-risk thing to try for eight to twelve weeks — that is the one use where the trials and the practical logic point the same way. If you have IBD, this is an add-on to discuss with your gastroenterologist, never a substitute for therapy that has been shown to control disease. And if you are healthy and buying butyrate for your gut, your colon, your metabolism or your longevity, the fibre you are not eating is a better-evidenced version of the same idea, at a lower price, delivered to the right address.
This article is research information, not medical advice. Butyrate salts and tributyrin are sold as dietary supplements and have no FDA approval for any indication; they are not treatments for irritable bowel syndrome, ulcerative colitis, Crohn’s disease, obesity or diabetes. Rectal butyrate enemas are a clinical procedure, not a self-administered supplement, and the doses in the trials described above were prepared and supervised by clinicians. Anyone with inflammatory bowel disease should treat butyrate strictly as a possible add-on to be discussed with a gastroenterologist and never as a replacement for prescribed therapy — and new or changing bowel symptoms, especially rectal bleeding or unexplained weight loss, need a diagnosis before they need a supplement. Sodium butyrate contributes sodium at gram-level doses.